Ischemic stroke with large-vessel occlusion can be treated with alteplase and/or endovascular therapy; however, the administration of each treatment is time sensitive.
F ast treatment of acute ischemic stroke is essential for disability-free survival.
1,2 The evolution of timedependent therapeutics for ischemic stroke refocuses the need to consider how to triage patients with suspected stroke in the field. Endovascular therapy (EVT), a minimally invasive endovascular procedure, is a more effective reperfusion method than intravenous alteplase for ischemic stroke with large-vessel occlusion (LVO). 3 The facilities and expertise needed for EVT are typically limited to urban tertiary hospitals. Conversely, intravenous alteplase is widely available and relevant for patients with ischemic stroke with and without LVO. Both treatments are time sensitive and may be given alone or in combination. 4, 5 Endovascular therapy has resulted in the new problem of identifying patients with probable LVO such that they could be preferentially moved to an EVT center. [6] [7] [8] [9] [10] Patients who received EVT with long interhospital transfer delays experienced worse outcomes than those without interhospital transfer. 11 Neurovascular imaging is the standard to determine EVT eligibility, but high-quality imaging in the field (eg, a mobile stroke unit capable of computed tomographic angiography 12 ) is not available for most patients. Several clinical scores for use by paramedics modeled after the National Institutes of Health Stroke Scale have been developed. 13 Three commonly used scales are the Cincinnati Prehospital Stroke Severity Scale (C-STAT), the Rapid Arterial Occlusion Evaluation (RACE), and the Los Angeles Motor Scale (LAMS), each with varying predictive value. [14] [15] [16] We sought to model the best transport strategies for acute stroke, balancing the benefit of early alteplase treatment, the greater efficacy of EVT, and declining benefit of both treatments over time. The study was conducted from February 1, 2017, to March 1, 2018.
Methods

Terminology and Simplifying Assumptions
Hospitals are classified as either thrombolysis or EVT centers. A thrombolysis center can administer intravenous alteplase (with onsite stroke expertise or telemedicine services) but does not provide EVT. An EVT center provides both EVT and intravenous alteplase treatment. In this analysis, 2 different treatment paradigms are discussed: the mothership and drip-andship treatment paradigms. We assume that treatments are always available. In the mothership paradigm, the patients are transported directly to an EVT center (potentially bypassing closer thrombolysis centers) and in the drip-and-ship paradigm, patients are first treated with intravenous alteplase at a thrombolysis center and then transferred to an EVT center. This study is an extension of previously published modeling frameworks (eTable 1 in the Supplement).
17, 18 We assume that stroke onset time is known and transport decisions are made after emergency medical services evaluation using an LVO screening tool and that the decision does not change en route. We assume that patients with occlusions within the guideline treatment time window and without medical contraindications to thrombolysis are eligible for alteplase and that patients with LVOs are eligible for EVT.
Last, because the rate of spontaneous early recovery among patients with LVO is low, we assume that patients estimated to have an LVO achieve reperfusion only with treatment.
Because this is a modeling study using previously published data in aggregate, ethics board approval was not required at the University of Calgary, Alberta, Calgary, Canada.
Model Components
This model combines conditional probabilities of excellent outcome constructed from clinical trials of stroke treatment and therefore reflects population averages and applies at the population level. We have approached the problem practically using the probability of achieving excellent outcome (modified Rankin Scale [mRS] 0-1 at 90 days) within a given time from stroke onset to treatment. Patients with LVO (extracranial or intracranial internal carotid artery, middle cerebral artery-M1 segment, or proximal middle cerebral artery-M2 segment occlusion) will receive both alteplase and EVT either at the EVT center or in a drip-and-ship approach. For EVT, the time-dependent probability of excellent outcome was derived from the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke trials collaboration time to treatment analysis. 5 For alteplase, the time-dependent probability of excellent outcome was derived from an individual patient data metaanalysis (Table) . 4 For mothership transport, time from onset to treatment is the sum of time from onset to medical contact, ambulance response and time spent on the scene, travel to the EVT center, and door-to-needle time or door-to-groinpuncture time at the EVT center (alteplase treatment). For drip and ship, transport time from onset to treatment is the sum of time from onset to medical contact, ambulance response and time spent on the scene, travel to the thrombolysis center, and door-to-needle time at the thrombolysis center (alteplase treatment), time from thrombolysis administration to departure for the EVT center, travel from the thrombolysis center to the EVT center, and door-to-groin-puncture time at the EVT center (EVT treatment) (eFigure 1 in the Supplement). Three different time scenarios were used: scenario A describes an optimized system, scenario B assumes slow treatment at the thrombolysis center, and scenario C assumes slow treatment at both centers (eTable 2 in the Supplement). Because clinical screening is imperfect, patients without LVO (false-positives) will also be identified including (1) ischemic stroke without LVO, (2) intracerebral hemorrhage (ICH), and (3) stroke mimics. Patients with subarachnoid hemorrhage or cerebral venous sinus thrombosis are not considered in this study. Patients with ischemic stroke without LVO within the guideline treatment window will be treated with alteplase. For this, the time-dependent probability of excellent outcome was derived from an individual patient data metaanalysis (Table) . 4 Patients with ICH may eventually require a higher level of care; however, there is currently indeterminate evidence on the efficacy of emergency medical or surgical treatment.
19-23 By combining the excellent outcome rates from several trials of emergency ICH treatment, the probability of excellent outcome for ICH is estimated to be 0.24 and is assumed to be time invariant (Table) . [19] [20] [21] [22] [23] Because most stroke mimics are not immediately life threatening and do not have time-dependent treatment options, the probability of excellent outcome for these patients is considered time invariant (Table) .
24-28
Patient Diagnoses
Three prehospital LVO screening tools were modeled. The Los Angeles Motor Scale, a 5-point scale in which higher scores indicate ischemic stroke with LVO 16 ; RACE, a 9-point scale in The exponential common odds ratio decay presented in the HERMES collaboration time to treatment analysis was used. 5 This decay was extrapolated to symptom onset to treatment times less than 120 min. Using P(mRS 0-1|control) as the baseline, this was transformed into a second order polynomial function depicting P(mRS 0-1|EVT) over time. This decay is capped at a minimum probability of excellent outcome of 0.129, which is the P(mRS 0-1|control) in the HERMES data. P(mRS 0 -1|alteplase and OTT = ×) 0.2359 + 0.0000002× 2 -0.0004×; minimum value = 0.1328
The exponential decay presented in the Emberson et al 4 effect of treatment delay meta-analysis was used. This decay was extrapolated to onset to treatment times of <60 min. Because this study includes data from patients with both small and large occlusions, we adjusted this decay using NIHSS as a surrogate for occlusion location to estimate outcomes of alteplase treatment over time in patients with LVO. Using P(mRS 0-1|NIHSS 11+ and control) as the baseline value, this was transformed into a second-order polynomial function depicting P(mRS 0-1|alteplase and LVO) over time. At 4.5 h from onset, the function is set to a minimum value of 0.1328, which is the P(mRS 0-1) given no treatment in the patients with NIHSS 11+ in this meta-analysis. 4 Non-Large-Vessel Occlusion P(mRS 0 -1|alteplase and OTT = ×) 0.6343-0.00000005× 2 -0.0005×; minimum value = 0.4622
The exponential decay presented in the Emberson et al 4 effect of treatment delay meta-analysis was used. This decay was extrapolated to onset to treatment times of <60 min. Because this study includes data from patients with both small and large occlusions, we adjusted this decay using NIHSS as a surrogate for occlusion location to estimate outcomes of alteplase treatment over time in patients with nLVO. Using P(mRS 0-1|NIHSS 0-10 and control) as the baseline value, this was transformed into a second-order polynomial function depicting P(mRS 0-1|alteplase and nLVO) over time. At 4.5 h from onset, the function is set to a minimum value of 0.4622, which is the P(mRS 0-1) given no treatment in the patients with NIHSS 0-10 in this meta-analysis. 4 Intracerebral Hemorrhage
This was generated by combining the overall excellent outcome rate in several trials of intracerebral hemorrhage treatment. [19] [20] [21] [22] [23] The STICH-II trial in patients with spontaneous ICH of 10-100 mL showed that early surgery had no benefit over conservative treatment. 19 The FAST trial showed no difference between recombinant factor VII (at 2 different doses) and placebo There was also no significant interaction found between treatment effect and time from onset to treatment. 20 The INTERACT2 trial showed no difference between early intensive BP lowering (SBP <140 mm Hg within 1 h) and guideline-recommended therapy (SBP <180 mm Hg) in the primary outcome (death and disability at 90 d); however, a favorable shift in the overall distribution of mRS scores at 90 d was found. 21 The greatest benefit was found in patients who were able to achieve the greatest SBP reductions within1hofrandomization 22 ; however, randomization occurred a median of 3.7 h after ICH onset. Thus, it remains unknown if this time benefit would persist in the hyperacute window after onset. The INCH trial found no difference between fresh frozen plasma or prothrombin complex concentrate in 90-d clinical outcomes in patients with vitamin K antagonist-related hemorrhages. 23 Because none of these trials showed emergency treatment to be superior to standard of care, this probability is considered time invariant.
Stroke Mimics
P(mRS 0-1) 0.90 Because most stroke mimics do not have time-dependent treatment options, the probability of excellent outcome for these patients is considered to be time invariant and is set at 0.90 based on the outcomes of stroke-mimic patients in prior studies. a In probability notations, P followed by the open and closed parentheses indicates the probability of the statement within the parentheses occurring and the | symbol indicates given in the conditional probability statement. 
Visualizations
Results are visualized using 2-dimensional (2-D) temporospatial diagrams. These diagrams depict a single thrombolysis center in the middle of the figures and a single EVT center at varying transport times below it. Concentric circles representing 5-minute increments of travel time radiate from the thrombolysis center. Color coding is used to represent the transport option with the greatest predicted probability of excellent outcome. Red and green indicate that drip and ship and mothership, respectively, estimate the best probability of excellent outcome. Areas where the 2 options estimate near-equivalent outcomes (probabilities within 0.01 of each other) are indicated using white stippling. Color intensity increases as the probability of achieving excellent outcome increases.
To show geographic context, results in California are also visualized. For the purposes of this illustration we have used data from The Joint Commission Quality Check Stroke Certification program as a surrogate for EVT capability. 30 We considered acute stroke-ready and advanced primary stroke centers to be thrombolysis centers and advanced comprehensive stroke centers to be EVT centers. Maps were generated using a desktop application developed for this research (DESTINE; Apple Inc). Esri's ArcGIS Software Development Kit was used to access a map of California. A 3 × 3-km grid was overlaid on the state and the geographic coordinates of the center of each grid section was passed through Google's Distance Matrix API (Google Inc) to estimate the ground transport time to each hospital under optimal driving conditions. These travel times were fed into the conditional probability models and the probability of excellent outcome for each strategy in each grid section was calculated. The grid sections were color coded in the same manner as the 2-D temporospatial diagrams.
Results
We modeled the probability of excellent outcome for both the drip-and-ship and mothership transport models, with varying transport times to and between centers (eAppendix and eFigure 1 in the Supplement). This model differs from prior published models. 17, 18 The earlier models assumed that patients were known to have an acute ischemic stroke with LVO.
In this model, patients are suspected to have an LVO based on an LVO screening tool. The treatment options for other possible diagnoses (non-LVO, ICH, and stroke mimics) were also included. eTable 1 in the Supplement provides a comparison of this and prior models. Several scenarios were created illustrating the association of varying transport times, treatment times, and screeningtool positive predictive values with decision making (eTable 3intheSupplement). Each scenario was visualized using 2-D temporospatial diagrams. These scenarios (eTable 2 in the Supplement) were also visualized in California.
When the patient is closest to the EVT center, mothership always estimates the greatest probability of excellent outcome. Patients with known contraindications to thrombolysis, including those beyond 4.5 hours from onset, should also be transported directly to an EVT center. When the patient is closest to the thrombolysis center, outcomes vary by transport time and treatment efficiency. With optimal treatment times (scenario A, eTable 2 in the Supplement) (door-to-needle time: 30 minutes; door-in-door-out time: 50 minutes; door-to-groin-puncture time: 60 minutes [mothership], 30 minutes [drip and ship]), when the thrombolysis and EVT centers are less than 60 minutes travel time apart, both strategies estimate near-equivalent probabilities of excellent outcome ( Figure 1 ). As the transport time between centers lengthens (90 or 120 minutes), a region where drip and ship clearly outweighs mothership appears; this includes locations close to the thrombolysis center and the narrow corridor in which patients would have to travel past the thrombolysis center en route to the EVT center. This drip-and-ship area expands as the centers are moved further apart and is especially pronounced when the centers are 120 minutes apart. In this instance, there is an area in the temporospatial plane where, if transported by mothership route, the patient foregoes the opportunity for treatment with alteplase under current guidelines as onset to needle time would exceed 4.5 hours.
In scenario B (eTable 2 in the Supplement) (door-toneedle time: 60 minutes [thrombolysis center], 30 minutes [EVT center]; door-in-door-out time: 120 minutes; door-togroin-puncture time 60 minutes [mothership], 30 minutes [drip-and-ship]), the outcome of slowing treatment at thrombolysis centers is shown; drip and ship is no longer associated with the greatest probability of excellent outcome when the travel time between centers is 60 minutes or less ( Figure 2 ). Even as the travel time between centers increases, drip and ship clearly outweighs mothership only when travel time would preclude patients from receiving alteplase in the mothership model.
In scenario C (eTable 2 in the Supplement) (doorto-needle time: 60 minutes; door-in-door-out time: 120 minutes; door-to-groin-puncture time: 90 minutes [mothership], 60 minutes [drip-and-ship]), we consider slow treatment times at both centers. Here, drip and ship outweighs mothership only when travel time would preclude alteplase administration in the mothership scenario or if the centers are 120 minutes apart and the patient is in the immediate vicinity of the thrombolysis center ( Figure 3 ).
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The results for all 3 time scenarios, using the LAMS screening tool, in California are shown in Figure 4 (enlarged maps of Los Angeles and San Francisco in eFigures 2 and 3 in the Supplement). Consistent with the 2-D temporospatial diagrams in an optimal scenario, drip and ship outweighs mothership only when the thrombolysis center is far from EVT centers. In Figure 4A , both strategies estimate equivalent outcomes in the greater Los Angeles area. However, drip and ship is the best option for patients in Bakersfield, which is an approximate 2-hour drive from Los Angeles. In Figure 4B , where treatment at the thrombolysis center is slow, the areas where drip and ship clearly outweigh mothership have shrunk and are now the best option only for patients near Fresno, San Luis Obispo/Santa Maria, Redding, and a portion of Mendocino County. When treatment times are slow at both thrombolysis and EVT centers ( Figure 4C ), areas where drip and ship clearly outweigh mothership have decreased in size compared with Figure 4A , but remain larger than those in Figure 4B .
When using RACE scores of 5 or higher (higher positive predictive values than LAMS scores ≥4) to identify patients with probable LVO, a similar pattern of results is obtained. However, the area where mothership estimates the best outcomes enlarges slightly (eFigures 4-6 in the Supplement). Overall, the probability of excellent outcome decreases because a greater proportion of patients with LVO, who have inherently poorer outcomes, is identified. When using C-STAT scores of 2 or higher (lower positive predictive value than LAMS scores ≥4) to identify probable LVO, the dripand-ship area expands (eFigures 7-9 in the Supplement), and the overall probability of excellent outcome increases as fewer patients with LVO are identified. Overall, the choice of prehospital scale does not substantively change the transport decision, as these scales have similar positive predictive values and the prevalence of LVO is low. The scenarios outlined deal with the complex interaction of several factors. The outcome of varying a single factor on the models is detailed in eTable 4 in the Supplement. Travel time between thrombolysis center (circle) and endovascular therapy center (diamond).
Green indicates mothership estimates the greatest P(mRS 0-1) Red indicates drip and ship estimates the greatest P(mRS 0-1) Stippling indicates |P(mRS 0-1|mothership) − P(mRS 0-1|drip and ship)| <.01.
Two-dimensional temporospatial diagrams depicting transport decision making for patients with suspected ischemic stroke with large-vessel occlusion, defined as Los Angeles Motor Scale Score 4 or higher, in an optimally performing system. The diagrams depict a single thrombolysis center in the middle of the Figure, depicted with a circle, and an endovascular therapy center (EVT), depicted by a diamond, at travel times of 10 (A), 30 (B), 60 (C), 90 (D), and 120 (E) minutes below it. There are 5-minute concentric travel time circles radiating from the thrombolysis center. Red indicates areas where drip and ship estimates the greatest probability of excellent outcome and green indicates areas where mothership estimates the greatest probability of excellent outcome. White stippling indicates areas where the optimal transport method supersedes the other areas by 1% or less. Area where the patient is closest to the EVT center is not shown because the mothership option is always best in this scenario. The degree of color saturation reflects the value of the probability of excellent outcome. The blue line represents the point where the onset to needle time in the mothership scenario is more than 270 minutes. 
Discussion
We have modeled and visualized a prehospital transport system for patients with acute ischemic stroke with suspected LVO using clinical trial data. The transport time threshold for bypass varies depending on treatment speed at the thrombolysis and EVT centers. This threshold is especially pronounced in scenario B, where door-to-needle time at thrombolysis centers is 60 minutes (door-in-door-out time, 120 minutes). This is the current reality in many stroke systems. Among hospitals in the Get With The Guidelines Target Stroke program, the postintervention median door-to-needle time was 67 minutes (interquartile range, 51-87 minutes). 31 Our results imply that, based on current treatment times, delivery should be regionally centralized to realize the full benefit of EVT on a population basis. Transport decision making is context specific. The radius of superiority for mothership changes based on the relative location of centers to each other and the treatment times at these centers; thus, model inputs need to be customized regionally. This need has potential implications for current accreditation standards and time metrics for quality stroke care. One way to drive change is to accredit centers that cannot meet efficiency targets and are within a short travel time to centers that can at a lower level than those meeting targets and to use such accreditation to guide bypass decisions for emergency medical services. The same considerations on efficient treatment times apply equally to thrombolysis and EVT centers. Population density and distribution, not modeled here, are also important when establishing regional transport and triage policy. Areas where both transport options produce nearequivalent outcomes may be treated differently jurisdiction to jurisdiction owing to economics, staffing, and/or redundancy in resources.
An ongoing randomized clinical trial is addressing the question of transport strategy in Barcelona (RACECAT [Direct Transfer to an Endovascular Center Compared to Transfer to the drip and ship estimates the greatest probability of excellent outcome and green indicates areas where mothership estimates the greatest probability of excellent outcome. White stippling indicates areas where the optimal transport method supersedes the other by 1% or less. Area where the patient is closest to the EVT center is not shown because the mothership option is always best in this scenario. The degree of color saturation reflects the value of the probability of excellent outcome. The blue line represents the point where the onset to needle time in the mothership scenario is more than 270 minutes. having an association with decision making, the results of RACECAT may not be generalizable to other jurisdictions with different geographic constraints. However, empirical data from RACECAT may be combined with this modeling approach to estimate the ideal strategy in regions where a randomized comparison is not feasible. The benefits of prehospital screening tools on transport decision making appear to be modest. Given the need to keep things simple in the prehospital environment, the most easily taught of these scales is likely to gain the most traction with emergency medical services. The merits of each tool should be considered when choosing one for implementation. Any intervention that would speed triage and transport in the prehospital environment may change the transport strategy estimated to be most favorable. However, this change would benefit all patients because time from onset to treatment would be shortened.
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In taking a population perspective, we have not taken into consideration the political and economic realities that sometimes govern system design. Stroke due to suspected LVO accounts for a minority of the total stroke population. In the Melbourne triaging study, LVO prevalence was only 14.5%. Depending on the screening tool used, anywhere from 18.4% to 21.4% of patients would have screened positive for LVO and therefore be guided by this model. 29 The remaining approximately 80% of patients would not be considered potential bypass candidates, and thus would require treatment at thrombolysis centers. Strategies need to be in place for urgent drip-and-ship transport for patients identified to have an LVO at the thrombolysis center but missed by the prehospital screen. Another consideration is the level of ambulance redundancy in each jurisdiction because mothership transport could leave ambulances out of their home region for longer than typical times. Although beyond the scope of this analysis, the potential volume increase at EVT centers, especially regarding patients with false-positive Red indicates areas where drip and ship estimates the greatest probability of excellent outcome and green indicates areas where mothership estimates the greatest probability of excellent outcome. White stippling indicates areas where the optimal transport method supersedes the other by 1% or less. Area where the patient is closest to the EVT center is not shown because the mothership option is always best in this scenario. The degree of color saturation reflects the value of the probability of excellent outcome. The blue line represents the point where the onset to needle time in the mothership scenario is more than 270 minutes. the greatest P(mRS he greatest P(mRS 0 ship) − P(mRS 0-1|d
Thrombolysis center Endovascular therapy center
Maps depicting the probability of excellent outcome and best predicted transport strategy for patients with suspected ischemic stroke with large-vessel occlusion, defined as Los Angeles Motor Scale Score of 4 or higher in California. In the maps, thrombolysis centers are depicted by black dots and endovascular therapy (EVT) centers are depicted by blue diamonds. A, System with optimized treatment times. B, System with fast treatment at EVT centers but slow treatment at thrombolysis centers. C, System with slow treatment at both thrombolysis and EVT centers. See the caption to Figure 1 for color guide. Gray areas indicate a lack of road infrastructure data; thus, transport times and optimal transport method could not be determined.
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stroke, should be considered when implementing a transport protocol.
Limitations
There are limitations to the model due to assumptions and available data. We have assumed the ICH treatment outcomes are time invariant; however, patients with ICH may require the higher level of care available at EVT centers (eg, neurosurgical teams and neurointensive care units) and that care may not be time invariant. Conversely, although unproven to date, it remains plausible that hyperacute medical treatment (eg, procoagulant drug <120 minutes from onset) could improve outcomes and, as such, patients might benefit from transport to the nearest stroke center. We have assumed that all patients with LVO will be eligible for EVT. However, this may not be the case and, as further data become available on the association between time and EVT eligibility, the models can be updated. The treatment of EVT patients will evolve 33 and changes in technology, treatment paradigms, or the use of mobile stroke units may affect the organization of stroke care. As further data become available, these models can be updated. The temporal spatial diagrams are transport-modality agnostic because they are based on transport time-not distance. However, the map of California was generated using ground transport times, and including air transport could change the results. Ground transport times are dependent on time of day and weather patterns. Thus, for jurisdictional planning, health systems may wish to evaluate several scenarios, including some in nonoptimal driving conditions, before deciding on a transport strategy. We used average times for time from onset to firstmedical contact and time on-scene, changing these will influence the model results. Finally, we have defined excellent outcome as an mRS score of 0 to 1 at 90 days; using another definition may affect model results.
Conclusions
Decision making for prehospital transport can be modeled using existing clinical trial data. These models are dynamic and can be adapted to different geographies or changing treatment realities. For ischemic stroke with suspected LVO, regional centralization of care is estimated to result in the best outcomes given current average treatment times. Where: P mRS 0-1|LVO is the overall probability of good outcome given a large vessel occlusion (Section C) P mRS 0-1|nLVO is the overall probability of good outcome given a non-large vessel occlusion (Section D) P mRS 0-1|ICH is the overall probability of good outcome given intracerebral hemorrhage (Section E) P mRS 0-1|SM is the overall probability of good outcome given a stroke mimic (Section 1 This decay was extrapolated to onset to treatment times of less than 60 minutes. As this study includes data from patients with both small and large occlusions we have adjusted this decay using NIHSS as a surrogate for occlusion location to estimate the effect of alteplase treatment over time in patients with LVO. Using P(mRS 0 -1|NIHSS 11+ & control) as the baseline value this was transformed into a 2 nd order polynomial function depicting P(mRS 0 -1|alteplase & LVO) over time. At 4.5 hours from onset the function is set to a minimum value of 0.1328 which is the P(mRS 0 -1) given no treatment in the patients with NIHSS 11+ in this meta-analysis. To generate the above equation the exponential common odds ratio decay presented in the HERMES collaboration time to treatment analysis was used. 2 This decay was extrapolated to symptom onset to treatment times less than 120 minutes. Using P(mRS 0 -1|control) as the baseline this was transformed into a 2 nd order polynomial function depicting P(mRS 0 -1|EVT) over time. This decay is capped at a minimum probability of excellent outcome of 0.129, which is the P(mRS 0 -1|control) in the HERMES data.
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Where in Mothership: 1 This decay was extrapolated to onset to treatment times of less than 60 minutes. As this study includes data from patients with both small and large occlusions we have adjusted this decay using NIHSS as a surrogate for occlusion location to estimate the effect of alteplase treatment over time in patients with nLVO. Using P(mRS 0 -1|NIHSS 0-10 & control) as the baseline value this was transformed into a 2 nd order polynomial function depicting P(mRS 0 -1|alteplase & nLVO) over time. At 4.5 hours from onset the function is set to a minimum value of 0.4622 which is the P(mRS 0 -1) given no treatment in the patients with NIHSS 0-10 in this meta-analysis. 1 Where t is as defined above in Section C
This was generated by combining the overall excellent outcome rate in several trials of intracerebral hemorrhage treatment. [3] [4] [5] [6] [7] The STICH-II trial in patients with spontaneous ICH of 10-100ml showed early surgery had no benefit over conservative treatment. 3 The FAST trial showed no difference between recombinant factor VII (at two different doses) and placebo. Of importance to this analysis there was also no significant interaction found between treatment effect and time from onset to treatment. 4 The INTERACT2 trial showed no difference between early intensive blood pressure lowering (SBP < 140 mmHg within one hour) and guideline recommended therapy (SBP <180 mmHg) in the primary outcome (death and disability at 90 days), however a favourable shift in the overall distribution of mRS scores at 90 days was found. 5 The greatest benefit was found in patients who were able to achieve the greatest SBP reductions within one hour of randomization, 6 however randomization occurred a median of 3.7 hours after ICH onset thus it remains unknown if this time benefit would persist in the hyperacute window after onset. The INCH trial found no difference between fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) in 90 day clinical outcomes in patients with vitamin K antagonist related hemorrhages. 7 As none of these trials showed emergency treatment to be superior to standard of care this probability is considered time invariant.
As most stroke mimics do not have time dependent treatment options, the probability of excellent outcome for these patients is considered to be time invariant and is set at 0.90 based on the outcomes of stroke mimic patients in prior studies. ). The PPV of the screening tool was used and the treatment options for other possible diagnoses (non-LVO, hemorrhagic stroke, and stroke mimics) were also included. There is uncertainty regarding which transport and treatment decision to make   There is only one decision making point (at the scene) and this decision is never reneged upon  
The model does not apply to found down or stroke on awakening patients -Time from onset to first medical contact was varied from 30 to 90 minutes  -Time from onset to first medical contact was assumed to be 30 minutes All patients with occlusions are eligible for alteplase and all patients with LVOs are eligible for EVT   -The caveat of no obvious contraindications to alteplase being present (Coumadin, recent surgery, late time window) was added For patients with LVOs reperfusion is only achieved through treatment (i.e. no spontaneous reperfusion)
 
Model Components
Model Outcome
Probability of mRS 0 -2 at 90 days 13 Probability of good outcome at 90 days where good outcome was defined at mRS 0 -2 at 90 days for endovascular therapy and mRS 0 -1 at 90 days for alteplase treatment. 
